Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is currently 2.6 days.

Adaptimmune Therapeutics Stock Down 3.1 %

ADAP opened at $0.59 on Monday. The firm has a 50-day simple moving average of $0.62 and a two-hundred day simple moving average of $0.86. Adaptimmune Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.05. The company has a market capitalization of $150.97 million, a PE ratio of -2.68 and a beta of 2.24. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ADAP shares. Mizuho reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Guggenheim cut their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright cut their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $2.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fullcircle Wealth LLC bought a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $33,000. Vontobel Holding Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 30,000 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $95,000. Virtu Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 21,769 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares during the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.